132 related articles for article (PubMed ID: 37072108)
21. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
22. [Current TNM system of the UICC/AJCC : the prognostic significance for differentiated thyroid carcinoma].
Stratmann M; Sekulla C; Dralle H; Brauckhoff M
Chirurg; 2012 Jul; 83(7):646-51. PubMed ID: 22273853
[TBL] [Abstract][Full Text] [Related]
23. Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence.
Huang BY; Hseuh C; Chao TC; Lin KJ; Lin JD
Endocr Pathol; 2011 Sep; 22(3):144-9. PubMed ID: 21647844
[TBL] [Abstract][Full Text] [Related]
24. Tall cell variant papillary thyroid carcinoma impacts disease-free survival at the 10 % cut-point on multivariate analysis.
Samankan S; Militello L; Seo G; Everest S; O'Malley Q; Spaulding SL; Xing M; Matloob A; Beute J; Chai R; Doyle S; Urken ML; Brandwein-Weber M
Pathol Res Pract; 2022 Aug; 236():154012. PubMed ID: 35834884
[TBL] [Abstract][Full Text] [Related]
25. The miR-199a-5p/PD-L1 axis regulates cell proliferation, migration and invasion in follicular thyroid carcinoma.
Lin J; Qiu Y; Zheng X; Dai Y; Xu T
BMC Cancer; 2022 Jul; 22(1):756. PubMed ID: 35818041
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive screening for PD-L1 expression in thyroid cancer.
Ahn S; Kim TH; Kim SW; Ki CS; Jang HW; Kim JS; Kim JH; Choe JH; Shin JH; Hahn SY; Oh YL; Chung JH
Endocr Relat Cancer; 2017 Feb; 24(2):97-106. PubMed ID: 28093480
[TBL] [Abstract][Full Text] [Related]
27. Finding the Optimal Age Cutoff for the UICC/AJCC TNM Staging System in Patients with Papillary or Follicular Thyroid Cancer.
van Velsen EFS; Visser WE; Stegenga MT; Mäder U; Reiners C; van Kemenade FJ; van Ginhoven TM; Verburg FA; Peeters RP
Thyroid; 2021 Jul; 31(7):1041-1049. PubMed ID: 33487121
[No Abstract] [Full Text] [Related]
28. PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
Zhang GQ; Wei WJ; Song HJ; Sun ZK; Shen CT; Zhang XY; Chen XY; Qiu ZL; Luo QY
Endocr Pract; 2019 Mar; 25(3):279-286. PubMed ID: 30913016
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.
Bai Y; Niu D; Huang X; Jia L; Kang Q; Dou F; Ji X; Xue W; Liu Y; Li Z; Feng Q; Lin D; Kakudo K
Diagn Pathol; 2017 Oct; 12(1):72. PubMed ID: 28974264
[TBL] [Abstract][Full Text] [Related]
30. DEATH RELATED TO PULMONARY METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER.
Leite AK; Kulcsar MA; de Godoi Cavalheiro B; de Mello ES; Alves VA; Cernea CR; Matos LL
Endocr Pract; 2017 Jan; 23(1):72-78. PubMed ID: 27749128
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 Expression and Ultrasound Characteristics in Papillary Thyroid Carcinoma and Its Effect on Recurrence.
Li R; Li M; Sun B; Qi M; Peng C; Li H; Zheng S; Liu Q; Jiang C
In Vivo; 2023; 37(6):2820-2828. PubMed ID: 37905619
[TBL] [Abstract][Full Text] [Related]
32. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
[TBL] [Abstract][Full Text] [Related]
34. Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes.
Balachandar S; La Quaglia M; Tuttle RM; Heller G; Ghossein RA; Sklar CA
Thyroid; 2016 Feb; 26(2):219-26. PubMed ID: 26854950
[TBL] [Abstract][Full Text] [Related]
35. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.
Yu XM; Schneider DF; Leverson G; Chen H; Sippel RS
Thyroid; 2013 Oct; 23(10):1263-8. PubMed ID: 23477346
[TBL] [Abstract][Full Text] [Related]
36. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
[TBL] [Abstract][Full Text] [Related]
37. Do Molecular Profiles of Primary
Gomes-Lima CJ; Shobab L; Wu D; Ylli D; Bikas A; McCoy M; Feldman R; Lee W; Rao SN; Jensen K; Vasko V; Castro LC; Jonklaas J; Wartofsky L; Burman KD
Front Endocrinol (Lausanne); 2021; 12():623182. PubMed ID: 33716974
[TBL] [Abstract][Full Text] [Related]
38. Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma.
Tunca F; Sormaz IC; Iscan Y; Senyurek YG; Terzioglu T
J Endocrinol Invest; 2015 Dec; 38(12):1327-34. PubMed ID: 26280320
[TBL] [Abstract][Full Text] [Related]
39. Factors affecting disease-free status of differentiated thyroid carcinoma patients.
Thamnirat K; Utamakul C; Chamroonrat W; Kositwattanarerk A; Anongpornjossakul Y; Sritara C
Asian Pac J Cancer Prev; 2015; 16(2):737-40. PubMed ID: 25684517
[TBL] [Abstract][Full Text] [Related]
40. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
